Photo by nampoh from unsplash
Key Points Question What is the comparative effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) antagonists for older patients with inflammatory bowel diseases (IBDs)? Findings In a comparative… Click to show full abstract
Key Points Question What is the comparative effectiveness and safety of vedolizumab vs tumor necrosis factor (TNF) antagonists for older patients with inflammatory bowel diseases (IBDs)? Findings In a comparative effectiveness study of 754 older patients, vedolizumab use was associated with a higher risk of treatment failure compared with TNF antagonists, without any difference in risk of serious infections, particularly for patients with Crohn disease. Meaning This study suggests that vedolizumab is associated with a higher risk of treatment failure compared with TNF antagonists, without offering any safety advantage for older patients with IBD.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!